A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group
about
Anti-endotoxin vaccines: back to the futureHeat shock protein gene expression and survival in critical illnessTowards clinical applications of anti-endotoxin antibodies; a re-appraisal of the disconnectSimilarities and disparities between core-specific and O-side-chain-specific antilipopolysaccharide monoclonal antibodies in models of endotoxemia and bacteremia in miceComplement-independent binding of microorganisms to primate erythrocytes in vitro by cross-linked monoclonal antibodies via complement receptor 1Hemolytically active (acylated) alpha-hemolysin elicits interleukin-1beta (IL-1beta) but augments the lethality of Escherichia coli by an IL-1- and tumor necrosis factor-independent mechanism.Protection against lipopolysaccharide-induced death by fluoroquinolones.Monoclonal antibodies to endotoxin in the management of sepsis.Therapies directed against endotoxin--has the time come?A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharidesAnti-LPS antibodies protect against Klebsiella pneumoniae by empowering neutrophil-mediated clearance without neutralizing TLR4Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis.Tolerance to endotoxin-induced expression of the interleukin-1 beta gene in blood neutrophils of humans with the sepsis syndrome.Nitric oxide and septic shock. From bench to bedsideEarly hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation.An anti-idiotype antibody which mimics the inner-core region of lipopolysaccharide protects mice against a lethal challenge with endotoxin.Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.Activity of lipopolysaccharide-binding protein-bactericidal/permeability-increasing protein fusion peptide in an experimental model of Pseudomonas sepsis.Influence of antibiotic and E5 monoclonal immunoglobulin M interactions on endotoxin release from Escherichia coli and Pseudomonas aeruginosa.Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.Reprogramming the host response in bacterial meningitis: how best to improve outcome?The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndromeReactivation of arthritis induced by small bowel bacterial overgrowth in rats: role of cytokines, bacteria, and bacterial polymersThe pulmonary physician and critical care. 3. Pharmacotherapy in lung injury.Role of endotoxemia in cardiovascular dysfunction and lethality: virulent and nonvirulent Escherichia coli challenges in a canine model of septic shock.Enhanced protection by use of a combination of anticapsule and antilipopolysaccharide monoclonal antibodies against lethal Escherichia coli O18K5 infection of mice.Antiendotoxin activity of cationic peptide antimicrobial agents.Passive immunization to outer membrane proteins MLP and PAL does not protect mice from sepsis.Disturbances of the hypothalamic-pituitary-adrenal axis and plasma electrolytes during experimental sepsisHuman bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteriaStudies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis.Role of alpha-2-macroglobulin and bacterial elastase in guinea-pig pseudomonal septic shockAlpha-2-macroglobulin as the major defence in acute pseudomonal septic shock in the guinea-pig modelLack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis.Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide.Endotoxin: Back to the FutureGram-negative sepsis: a dilemma of modern medicineIntravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis.Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins.Immunoparalysis and adverse outcomes from critical illness.
P2860
Q22305428-9CE47DF4-F5A8-4D43-A89F-EB00897C2A90Q24795441-8B909DEE-DD13-4BE6-9051-F52F0538901AQ26996658-10CB94E6-4E79-423C-8CFE-F94E8FA7FB8FQ28379429-0B7EE0FA-002E-4CB2-AFE3-5F110AF53EC9Q30452831-EAE66657-31E2-4056-93FA-E0BF7ED83280Q30453726-6037A8D2-9685-44DE-885F-ABFB35F4852FQ33594884-4D48B4A9-0D9F-4D51-95B4-41993D6ECC6AQ33606835-F5425287-7047-4AA1-974F-161F023CB4CDQ33606855-4B8903F9-9FCA-4F30-BD50-8690B5367E32Q33608312-285F463C-0311-4D28-B6B8-B09DBF45D9FEQ33631108-FFD22066-A5B3-4DC7-B18A-309069D974F2Q33754022-2C809FBF-2242-420E-BB7D-B0A47A7CEB60Q33892692-10EC2610-A81E-4957-8D33-502DC9110EE6Q34187914-CFA4B104-C979-46CC-811E-C9A30DED05A8Q34480723-076C06B3-3CAA-429B-8C29-432E0663B090Q34537934-45ABBB45-63FC-4C7B-8B11-7A6197988A8CQ34577529-B89967D7-3192-4277-AD5A-77319BBA1B69Q35121122-6FDD0E67-FA51-4C2F-B89D-ABE1BB42FCCEQ35122113-EEB15B26-47A7-454E-B10F-0EA62BEC4F3EQ35176262-36B57744-73A7-42E8-886F-12F187F49B19Q35176266-BF8E7B53-C701-45A6-9F19-A51DB55E21FCQ35228954-BB2391C1-94B2-4CC3-B8CE-DA0DA6E838F3Q35418279-6C1988C4-6363-4251-BD8A-D6B7AEE51FA1Q35428346-E928A108-8088-478E-91E2-A0AD67B17A6AQ35465958-4233CE67-8433-4EBB-983C-CDF6B2DB36F5Q35472569-5BE112BD-AFF7-49A8-9EA0-01ED878FE9FBQ35530704-523BA1CD-3862-442A-BA53-E331AE98C494Q35586916-1AF41219-D9D2-40F5-A202-57C1169554BDQ35690018-4FC9607D-C8AA-4BB7-9E4C-493ED05470A7Q35822718-A92E6196-1846-4C39-AABE-B6F19A50E5F7Q35897129-430F4012-3A66-4065-839A-D21E16BBC39DQ36019024-992F870A-5DAB-4C7A-80EA-571BE22DC5CAQ36029189-BDB19F93-374B-421E-B02F-C87FCB93C7FCQ36310139-201071F0-2551-4CBF-B337-7BEE422C1D56Q36361146-7CEF8134-358F-4072-A940-FF4CAB3F349BQ36477069-869C7247-9EE3-43EA-A70A-E68E064D08DAQ36639504-71A62213-681E-4C8F-90DD-DC5EC85401A1Q36658182-4D787EA4-9678-4B41-96FB-A29932220764Q36757740-7C66E40A-07AE-4457-8CD8-89F7F94187C8Q36775843-49DF71E5-D6E0-4BF1-9B69-2479A959DFD3
P2860
A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group
description
1991 nî lūn-bûn
@nan
1991 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
A controlled clinical trial of ...... s. The XOMA Sepsis Study Group
@ast
A controlled clinical trial of ...... s. The XOMA Sepsis Study Group
@en
A controlled clinical trial of ...... s. The XOMA Sepsis Study Group
@nl
type
label
A controlled clinical trial of ...... s. The XOMA Sepsis Study Group
@ast
A controlled clinical trial of ...... s. The XOMA Sepsis Study Group
@en
A controlled clinical trial of ...... s. The XOMA Sepsis Study Group
@nl
prefLabel
A controlled clinical trial of ...... s. The XOMA Sepsis Study Group
@ast
A controlled clinical trial of ...... s. The XOMA Sepsis Study Group
@en
A controlled clinical trial of ...... s. The XOMA Sepsis Study Group
@nl
P2093
P921
P356
P1476
A controlled clinical trial of ...... s. The XOMA Sepsis Study Group
@en
P2093
G Emmanuel
M A Martin
M McCarthy
N R MacIntyre
R B Kohler
R L Greenman
R M Schein
R P Wenzel
P304
P356
10.1001/JAMA.266.8.1097
P407
P577
1991-08-28T00:00:00Z